Comparative Pharmacology
Head-to-head clinical analysis: NUROMAX versus ZEMURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUROMAX versus ZEMURON.
NUROMAX vs ZEMURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neuromuscular blocking agent; competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing depolarization and muscle contraction.
Rocuronium is a nondepolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing muscle contraction.
0.1 mg/kg IV bolus, then 0.015 mg/kg IV as needed for neuromuscular blockade.
0.6-1.2 mg/kg IV bolus for intubation; maintenance 0.1-0.2 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
Terminal half-life: 1.5-2.5 hours; prolonged in renal impairment (up to 5 hours) and hepatic disease
Terminal elimination half-life is approximately 2.3 hours (range 1.7-3.1 hours) in adults with normal renal function. Clinical context: May be prolonged in hepatic or renal impairment.
Renal: 80-90% unchanged; biliary: 10-20%
Primarily renal (70-80% as unchanged drug and metabolites) and biliary (20-30% as unchanged drug and metabolites).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent